
    
      Participants will receive up to a total of 30 daily doses of study drug (15 days of daily
      IW-6463, only; 15 days of daily placebo, only) administered across two 15-day dosing periods
      (Period 1 and Period 2). The dosing periods will be separated by a 27-day washout.
      Participants will be randomized to a sequence of receiving IW-6463 for Period 1 and then
      placebo for Period 2, or vice versa.
    
  